Skip To Main Content
M. Di Bartolomeo on Muck Rack

M. Di Bartolomeo

As seen in: Annals of Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with M.

Contact M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety and efficacy profile of ramucirumab alone or combined with paclitaxel in metastatic gastric cancer (MGC): A real-life overview of compassionate-use named patients (pts) (RAMoss study)

|
By Fondazione IRCCS, M. M. Laterza, M. Di Bartolomeo, M. Niger
| Annals of Oncology Verified
Background: Ramucirumab, an anti-VEGFR2 monoclonal antibody, improved the outcome of MGC pts both as a single agent and in combination with paclitaxel, achieving recent approval in second-line therapy. However, few ”real life” data are available. The objective of the RAMoss study is to evaluate the safety and efficacy of ramucirumab in the Italian compassionate-use program, prior to marketing authorization. Methods: The primary endpoint was safety and secondary were overall response rate (ORR), …
Open in Who Shared Issue with article?
See all 1 articles